Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753170 | 0.86 | CACNA1F (0.48) | PTGS1SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL13316478 | 0.85 | ABCB1 (0.46) | PTGS1SMN1; SMN2ALDH1A1LMNAABCB1 | |
| SCHEMBL27778831 | 0.84 | ABCB1 (0.48) | PTGS1SMN1; SMN2ALDH1A1LMNAABCB1 | |
| SCHEMBL2568217 | 0.79 | PTGS1 (0.73) | PTGS1SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL12000493 | 0.79 | PTGS1 (0.60) | PTGS1SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL31092506 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2POLBALDH1A1LMNAMAPT | |
| SCHEMBL17874015 | 0.77 | PTGS1 (0.58) | PTGS1SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL2570531 | 0.77 | PTGS1 (0.67) | PTGS1SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL2565828 | 0.75 | PTGS1 (0.56) | PTGS1SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL13349506 | 0.75 | PTGS1 (0.56) | PTGS1SMN1; SMN2POLBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137340-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | GLATTHAR RALF | 2010-06-03 | — | — | US | disclosed |
| US-20100137340-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | GLATTHAR RALF | 2010-06-03 | — | — | US | disclosed |
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-2132210-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | Novartis AG (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008107418-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107418-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137340-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | GRM1, GRM2, GRM3 | PTGS1 443/4885SMN1; SMN2 1132/4885POLB 4500/4885 |
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | PTGS1 1228/4885SMN1; SMN2 2979/4885POLB 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.